熱門資訊> 正文
Kiniksa Pharmaceuticals报告第一季度业绩好坏参半;上调24财年前景
2024-04-23 19:37
- Kiniksa Pharmaceuticals, Ltd.(KNSA) 0
- BlackRock ETF Trust II BlackRock Short-Term California Muni Bond ETF(CALY) 0
- Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q1 GAAP EPS of -$0.25 misses by $0.09.
- Revenue of $79.86M (+65.2% Y/Y) beats by $1.4M.
- As of March 31, 2024, Kiniksa had $213.6 million of cash, cash equivalents, and short-term investments and no debt.
- Financial Guidance
- Kiniksa expects 2024 ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
- Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
More on Kiniksa Pharmaceuticals
- Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals
- Historical earnings data for Kiniksa Pharmaceuticals
- Financial information for Kiniksa Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
